- Home
- AVIR vs PROK Comparison
AVIR vs PROK Comparison
Compare AVIR & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | PROK |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | 231 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.1M | 359.4M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AVIR | PROK |
|---|---|---|
| Price | $5.12 | $1.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $9.42 | $6.25 |
| AVG Volume (30 Days) | 280.0K | ★ 1.3M |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $2.87 | $1.30 |
| 52 Week High | $6.45 | $3.48 |
Technical Indicators
Market Signals| Indicator | AVIR | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 44.38 | 43.55 |
| Support Level | $5.09 | $1.56 |
| Resistance Level | $5.76 | $2.01 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 23.45 | 17.05 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.